In the fifth episode of The Saving Dose, Dr. John Hsu and William Pedranti go inside opioid use disorder from the ground up: what it actually is, what causes it, why the people most affected by it are being failed by a system that was never designed to treat a chronic disease like a chronic disease, and why the gap between the medications that work and the patients who receive them keeps growing.

The episode opens with William's recent trip to Washington D.C., where he met with members of Congress from both sides of the aisle and visited the White House to discuss the opioid crisis facing America's veterans. What he found: unanimous agreement that the crisis is real, and a treatment infrastructure that cannot come close to meeting the need. 418,000 veterans are living with opioid use disorder. Only 6,500 are currently being treated. 44 die every day from suicide and opioid overdose.

This episode covers why opioid use disorder is a chronic medical condition and not a willpower problem, what the science actually says about brain chemistry versus environment, and why treating the addiction without treating the whole person produces a predictable failure rate that the system keeps misreading as patient noncompliance.

In this episode:

What opioid use disorder actually is clinically, why it is not the same as opioid dependency, and why the healthcare system keeps confusing the two in ways that cost lives.

Why 50 to 80% of patients with OUD also carry a co-occurring psychiatric diagnosis including depression, anxiety, PTSD, or ADHD, and what happens when clinicians treat the addiction without addressing what drove the person to opioids in the first place.

The Vietnam veteran study: why 80 to 90% of soldiers who were addicted to heroin stopped using when they returned to a changed environment, what that tells us about the role of circumstance in addiction, and why it does not mean addiction is just a choice.

Adverse childhood experiences: why a history of four or more ACEs raises the risk of developing opioid use disorder fourfold, and why that number matters for how treatment should be designed.

Why only 4 to 6% of people who misuse prescription opioids ever progress to illicit heroin or fentanyl, and what that means for the prescribing policy decisions that have left millions of chronic pain patients undertreated.

The prescription cliff: what happens when a patient leaves the pharmacy and why, in John's words, remote medication adherence monitoring stops at the patient's front door.

Why the medications work, why the stigma around them is wrong, and why a patient on Suboxone or methadone still has every right to receive opioids for acute or chronic pain.

Why opioid use disorder has to be treated like what it is: a chronic medical condition that requires sustained management, not a thirty-day program and a handshake at discharge.

William's story about a friend's brother who, after thirty years of managing addiction as a chronic disease, voluntarily checked himself back into residential treatment before relapse rather than after.

About the Hosts

John Hsu, MD is the Founder and CEO of iPill and a practicing anesthesiologist with 25 years in pain management and addiction medicine. He has taken multiple products through FDA approval and commercial launch. Connect with John: https://www.linkedin.com/in/john-hsu-md-300a8b2a/

William Pedranti is the COO of iPill, a Georgetown Law graduate, and co-founder of PENG Life Science Ventures. He has taken a biotech company from founding through FDA approval, commercial launch, and exit. Connect with William: https://www.linkedin.com/in/williampedranti/

Kendra Allen is the CRO of iPill with 20 years in behavioral health revenue strategy, payer contracting, and regulatory navigation. She founded and exited a national healthcare consulting firm. Connect with Kendra: https://www.linkedin.com/in/kendra-allen-cro/

Website: thesavingdose.com

This podcast is for educational purposes only and does not constitute medical advice. Consult a qualified healthcare professional before making any treatment decisions.

#OpioidCrisis #AddictionRecovery #OpioidUseDisorder #MOUD #MedicationAdherence #BehavioralHealth #AddictionMedicine #VeteransMentalHealth #OpioidTreatment #SubstanceUseDisorder #HealthcarePodcast #TheSavingDose #ChronicDisease #PTSD #PublicHealth #MentalHealth #DrugPolicy #OpioidEpidemic #VeteransHealth

In the fourth episode of The Saving Dose, William Pedranti and Kendra Allen continue their conversation on the operational reality inside opioid treatment programs and get into the part of addiction recovery that almost nobody in the industry talks about publicly: what happens after the patient walks out the door, why most of them do not come back, and why the system was never designed to know the difference.

This episode covers the economics of running an addiction treatment practice, why alcohol addiction is in many ways harder to treat than opioid addiction, how the shame and guilt cycle quietly destroys the clinical relationship, and what one text message from a counselor named Ashley revealed about how close patients can be to relapse without anyone knowing.

In this episode:

Why money is the single biggest barrier to addiction treatment in America, and why insurance coverage gaps mean that many people who need care most are the least able to access it.

Why alcohol addiction may be harder to treat than opioid addiction, and what social acceptability has to do with it.

The shame and guilt cycle: why patients who relapse between visits almost never tell their provider the truth, why that silence is a predictable system failure rather than a character flaw, and what a story about poppy seed muffins reveals about how broken the feedback loop is.

What opioid treatment programs are actually up against: staffing shortages, burnout, Medicaid reimbursement pressure, patient churn, and a geography problem that puts clinics hours away from the patients who need them most.

Alumni programs: what they are, why they matter, and why the story of Ashley texting a patient she had not spoken to in a year captures exactly what the gap between visits actually costs.

How the addiction census grows in economic downturns, why designer drugs and animal tranquilizers are creating new crisis points in cities like Seattle, and what Kendra means when she says we are here to help the desperate.

Where opioid treatment programs are headed, what the industry is trying to embrace, and why the providers who stay in this space are there for reasons that have nothing to do with the money.

William's personal story: picking up a close friend's brother from a sober living facility after thirty days, and what it means when someone says recovery is sometimes day to day and sometimes minute to minute.

About the Hosts

John Hsu, MD is the Founder and CEO of iPill and a practicing anesthesiologist with 25 years in pain management and addiction medicine. He has taken multiple products through FDA approval and commercial launch. Connect with John: https://www.linkedin.com/in/john-hsu-md-300a8b2a/

William Pedranti is the COO of iPill, a Georgetown Law graduate, and co-founder of PENG Life Science Ventures. He has taken a biotech company from founding through FDA approval, commercial launch, and exit. Connect with William: https://www.linkedin.com/in/williampedranti/

Kendra Allen is the CRO of iPill with 20 years in behavioral health revenue strategy, payer contracting, and regulatory navigation. She founded and exited a national healthcare consulting firm. Connect with Kendra: https://www.linkedin.com/in/kendra-allen-cro/

Website: thesavingdose.com

Disclaimer: This podcast is for educational purposes only and does not constitute medical advice. Consult a qualified healthcare professional before making any treatment decisions.

#OpioidCrisis #AddictionRecovery #OpioidUseDisorder #MedicationAdherence #MOUD #BehavioralHealth #AddictionMedicine #OpioidTreatment #SubstanceUseDisorder #HealthcarePodcast #TheSavingDose #RecoveryPodcast #MentalHealth #PublicHealth #PatientRetention #MAT #AlcoholAddiction #OTPChallenges #PatientChurn #AddictionTreatment

In the third episode of The Saving Dose, William Pedranti sits down with Kendra Allen to map the full continuum of addiction treatment in America and go inside the operational reality of the clinics trying to deliver it. This is not a conversation about clinical failure. It is a conversation about what happens in the seven days between appointments, why most practices have no visibility into that window, and why that invisibility is where most recoveries end.

This episode covers the levels of care most families do not know exist until they are desperate, what medication-assisted treatment actually is and why the stigma around it is costing lives, how opioid treatment programs are bleeding patients they cannot afford to lose, and what Kendra calls the black box: the gap between the clinic visit and the outcome where providers are flying blind and patients are on their own.

In this episode:

What you can do when a loved one needs addiction treatment, why calling your insurance company may not be the right first step, and how to potentially navigate a system that was not designed to be navigated by someone in crisis.

The full continuum of care from detox through residential to partial hospitalization, intensive outpatient, and MAT: what each level means, what it may cost, and what could drive the decision between them.

Why medication-assisted treatment may not be giving patients a synthetic high, where the stigma around MAT can come from, and what that stigma may do to the patients who need it most.

The shame cycle: some reasons why patients who relapse between visits do not tell their providers the truth, what that dishonesty can cost the clinical relationship, and why it may be a predictable system failure rather than a character flaw.

What it looks like inside a clinic when a patient walks in with a dirty drug test and a story about poppy seed muffins, and what a provider is supposed to do with that.

Why the seven to fourteen days of medication a patient takes home can be one of the highest-risk windows in recovery, and what can happen when that medication exists in a household where someone else is also struggling.

Outcomes happen between visits. What Kendra means by that, what her definition of the black box actually is, and why closing it can be the central operational and clinical challenge facing opioid treatment programs in America.

Why patient churn is not a marketing problem or a clinical problem but an infrastructure problem.

About the Hosts

John Hsu, MD is the Founder and CEO of iPill and a practicing anesthesiologist with 25 years in pain management and addiction medicine. He has taken multiple products through FDA approval and commercial launch.

Connect with John: https://www.linkedin.com/in/john-hsu-md-300a8b2a/

William Pedranti is the COO of iPill, a Georgetown Law graduate, and co-founder of PENG Life Science Ventures. He has taken a biotech company from founding through FDA approval, commercial launch, and exit.

Connect with William: https://www.linkedin.com/in/williampedranti/

Kendra Allen is the CRO of iPill with 20 years in behavioral health revenue strategy, payer contracting, and regulatory navigation. She founded and exited a national healthcare consulting firm.

Connect with Kendra: https://www.linkedin.com/in/kendra-allen-cro/

Website: thesavingdose.com

This podcast is for educational purposes only and does not constitute medical advice. Consult a qualified healthcare professional before making any treatment decisions.

#OpioidCrisis #AddictionRecovery #OpioidUseDisorder #MedicationAdherence #MOUD #BehavioralHealth #AddictionMedicine #OpioidTreatment #SubstanceUseDisorder #HealthcarePodcast #TheSavingDose #RecoveryPodcast #MentalHealth #PublicHealth #PatientRetention #MAT #ChronicPain